From Mechanism To Longevity
We use mechanism of action (MoA) to develop bona fide gerotherapies
Get in touch
The Challenge
Aging is the # 1 risk factor for most common diseases. The list includes cancer, infectious, metabolic, and neurodegenerative diseases. A gerotherapy is a drug that addresses an underlying core aging molecular mechanism. Because there are multiple factors that contribute to aging, targeting them precisely is critical.
Learn moreIntroducing MOAT - the BIOIO platform
MOAT (mechanism of action technologies) is a MoA-driven clinical indication prediction engine. MOAT combines both experimental and computational approaches. The strengths of our approach are two-fold. First, ensuring an accurate understanding of a small molecule’s MoA is vital to establishing contexts in which it might be effective and what its side effect liabilities might be. Second, by ensuring the compounds we advance are bona fide gerotherapies, we ensure a ‘pipeline in a pill’ - where each asset can be used in multiple clinical indications. Both aspects of the MOAT platform ensure we are focused on drug efficacy, which is a main reason therapies fail.
Learn more
The first clinical application
BIOIO is focusing on therapies for diabetes and its consequences. By targeting two crucial metabolic pathways—fatty acid oxidation and sphingolipid biosynthesis—BIOIO aims to develop effective, first-in-class treatments, both standalone therapies and genetically informed combination strategies, to combat metabolic disease. Our targets, the NMNAT-SIRT axis and SPT, are strongly associated with prolonged healthspan.
Learn more
